ABT vs ECG · P/E 25, rev $44.33B vs P/E 35, rev $3.75B
Abbott Laboratories (ABT) versus Everus Construction Group Inc (ECG) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Everus Construction Group Inc (ECG) is a engineering & construction company listed on NYSE.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported ECG revenue for 2025-12-31 was $3.75B. Net income was $201.8M. Revenue was up 31.5% from 2024-12-31 to 2025-12-31. ECG currently screens at market cap $7.87B and trailing P/E 35.3.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. ECG currently screens at market cap $7.87B and trailing P/E 35.3.
Not investment advice. Open the ABT and ECG stock pages for the full models.
Not investment advice.